An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
UNITY Biotechnology, Inc. announces two poster presentations at the ARVO 2024 Annual Meeting focusing on senolytic candidates for patients with DME and wet AMD, showcasing potential benefits in disease management.
UNITY Biotechnology, Inc. annuncia due presentazioni di poster al Meeting Annuale ARVO 2024, concentrando l'attenzione sui candidati senolitici per pazienti con DME e AMD umida, evidenziando i potenziali benefici nella gestione della malattia.
UNITY Biotechnology, Inc. anuncia dos presentaciones de póster en la Reunión Anual de ARVO 2024, enfocándose en candidatos senolíticos para pacientes con DME y AMD húmeda, mostrando los beneficios potenciales en la gestión de la enfermedad.
UNITY Biotechnology, Inc.에서 2024년 ARVO 연례 미팅에서 DME 및 습성 AMD 환자를 위한 세놀리틱 후보에 초점을 맞춘 두 개의 포스터 발표를 공개합니다. 이는 질병 관리에서의 잠재적 혜택을 보여줍니다.
UNITY Biotechnology, Inc. annonce deux présentations de posters lors de la Réunion Annuelle ARVO 2024, se concentrant sur les candidats sénolytiques pour les patients atteints de DME et de DMLA humide, mettant en évidence les avantages potentiels dans la gestion de la maladie.
UNITY Biotechnology, Inc. kündigt zwei Posterpräsentationen auf der ARVO 2024 Jahrestagung an, die sich auf Senolytik-Kandidaten für Patienten mit DME und feuchter AMD konzentrieren, und die potenziellen Vorteile im Krankheitsmanagement hervorheben.
Positive
None.
Negative
None.
SOUTH SAN FRANCISCO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that the Company will present two poster presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting being held on May 5-9, 2024 in Seattle, Washington.
ARVO 2024 Presentation Details:
Title: Effect of Patient Baseline Characteristics on Response to UBX1325, a Novel Senolytic Candidate For Patients With DME: BEHOLD Phase 2 Study 48 weeks follow-up Posterboard Number: B0103 Date & Time: Monday, May 6, 2024 at 8:30 – 10:15 a.m. PDT Location: Exhibit Hall - Seattle Convention Center Presenter: Dante Joseph Pieramici, M.D., California Retina Consultants
Title: Senolytic drug candidate in wet AMD demonstrates benefit with Multifocal ERG testing Posterboard Number: B0391 Date & Time: Wednesday, May 8, 2024 at 2:15 – 4:00 p.m. PDT Location: Exhibit Hall - Seattle Convention Center Presenter: Raj K. Maturi, M.D., Midwest Eye Institute
Additional presentation details and abstracts are available on the ARVO 2024 website here.
About UNITY UNITY is developing a new class of therapeutics to slow, halt, or reverse diseases of aging. UNITY’s current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. More information is available at www.unitybiotechnology.com or follow us on X and LinkedIn.
What is UNITY Biotechnology announcing at the ARVO 2024 Annual Meeting?
UNITY Biotechnology will present two poster presentations focusing on senolytic candidates for patients with DME and wet AMD.
When is the ARVO 2024 Annual Meeting happening?
The ARVO 2024 Annual Meeting is scheduled to take place on May 5-9, 2024, in Seattle, Washington.
What are the titles of the poster presentations by UNITY Biotechnology?
The titles are 'Effect of Patient Baseline Characteristics on Response to UBX1325, a Novel Senolytic Candidate For Patients With DME: BEHOLD Phase 2 Study 48 weeks follow-up' and 'Senolytic drug candidate in wet AMD demonstrates benefit with Multifocal ERG testing'.
Who are the presenters for the poster presentations by UNITY Biotechnology?
The presenters are Dante Joseph Pieramici, M.D., California Retina Consultants and Raj K. Maturi, M.D., Midwest Eye Institute.
Where can additional presentation details and abstracts be found?
Additional details and abstracts can be found on the ARVO 2024 website.
unity biotechnology is developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging. unity's initial focus is on creating senolytic medicines to selectively eliminate senescent cells and thereby treat age-related diseases, such as osteoarthritis, eye diseases and pulmonary diseases. more information is available at www.unitybiotechnology.com.
